OmniAb
OABI
4.56
+0.21
+4.83%
OmniAb
US · OABI
#3556 by market cap
Listed 2021
4.56
+0.21
+4.83%
Live - 5344 symbols - heartbeat 220s ago
· 2026-10-08 09:14
Pre-market
4.25
-6.80%
After-hours
4.61
+1.10%
- Market cap
- 662.98M
- P/E (TTM)i
- -12.67
- P/Bi
- 2.55
- EPSi
- -0.57
- Div yieldi
- 0.00%
- 52W posi
- 79%
Reader sentiment
Are you bullish or bearish on OABI?
Anonymous reader poll. Unscientific, not investment advice.
About OmniAb
OmniAb, Inc. operates as a drug discovery company. The firm focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
- Founded
- 2015
- CEO
- Mr. Matthew W. Foehr
- Employees
- 89
- Headquarters
- Emeryville, California, United States of America
- Fiscal year end
- 12-31
- Website
- omniab.com
Company profile
- Exchange
- US
- Symbol
- OABI
- Market-cap rank
- #3556
- Listing date
- 2021-09-30
- Market cap
- 662.98M
- Float cap
- 539.20M
- Shares out
- 145.39M
- Float shares
- 118.24M
Sectors & themes
Quote time 2026-10-08 09:14:36 · For reference only, not investment advice and not tailored to your situation.